CCL2-CCR2 signaling axis in obesity and metabolic diseases.
J Cell Physiol
; 239(4): e31192, 2024 Apr.
Article
de En
| MEDLINE
| ID: mdl-38284280
ABSTRACT
Obesity and metabolic diseases, such as insulin resistance, type 2 diabetes, nonalcoholic fatty liver disease, and cardiovascular ailments, represent formidable global health challenges, bearing considerable implications for both morbidity and mortality rates. It has become increasingly evident that chronic, low-grade inflammation plays a pivotal role in the genesis and advancement of these conditions. The involvement of C-C chemokine ligand 2 (CCL2) and its corresponding receptor, C-C chemokine receptor 2 (CCR2), has been extensively documented in numerous inflammatory maladies. Recent evidence indicates that the CCL2/CCR2 pathway extends beyond immune cell recruitment and inflammation, exerting a notable influence on the genesis and progression of metabolic syndrome. The present review seeks to furnish a comprehensive exposition of the CCL2-CCR2 signaling axis within the context of obesity and metabolic disorders, elucidating its molecular mechanisms, functional roles, and therapeutic implications.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Récepteurs CCR2
/
Maladies métaboliques
/
Obésité
Limites:
Animals
/
Humans
Langue:
En
Journal:
J Cell Physiol
Année:
2024
Type de document:
Article
Pays d'affiliation:
Chine